Research programme: monoclonal antibody therapeutics - Mapp/Vanderbilt

Drug Profile

Research programme: monoclonal antibody therapeutics - Mapp/Vanderbilt

Latest Information Update: 25 Nov 2014

Price : $50

At a glance

  • Originator Mapp Biopharmaceutical; Vanderbilt University
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Ebola virus infections; Marburg virus disease

Most Recent Events

  • 18 Sep 2014 Early research in Ebola virus infections in USA (Parenteral)
  • 18 Sep 2014 Early research in Marburg virus disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top